Overview
- Wave Life Sciences, following Thursday's interim Phase 1 INLIGHT readout for its obesity drug WVE-007, saw its stock fall about 30%.
- A single 240mg dose cut visceral fat by 14% versus placebo over six months in participants with an average body mass index of 32.
- Safety results showed the drug was tolerated up to 600mg with no treatment stops or severe side effects, and serum Activin E stayed suppressed for at least seven months, pointing to infrequent dosing.
- The cohort’s lower average BMI than the ~37 common in later-stage trials makes clean comparisons to rivals harder, and a cross-trial comparison to semaglutide drew skepticism.
- Wave plans a Phase 2a start in Q2 2026 enrolling patients with BMI 35–50 and comorbidities, with dose updates and an ADA poster expected in May that could offer new signals.